Cancer Journal

Papers
(The TQCC of Cancer Journal is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Epidemiology of Triple-Negative Breast Cancer133
Lymphoma Classification72
Immunotherapy in Triple-Negative Breast Cancer36
Menin Inhibitors in Acute Myeloid Leukemia—What Does the Future Hold?28
Adjuvant and Neoadjuvant Treatment of Triple-Negative Breast Cancer With Chemotherapy27
Cytokine Release Syndrome Biology and Management27
Molecular Classification and Treatment of Diffuse Large B-Cell Lymphoma and Primary Mediastinal B-Cell Lymphoma24
PARP Inhibitors in Pancreatic Cancer19
Menopausal Hormone Replacement Therapy and Reduction of All-Cause Mortality and Cardiovascular Disease19
Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer18
The Immunotherapy Revolution in Kidney Cancer Treatment18
Novel Therapeutic Approaches and the Evolution of Drug Development in Advanced Kidney Cancer18
Challenges and Errors in Genetic Testing15
HIV Lymphoma and Burkitts Lymphoma14
Triple-Negative Breast Cancer13
How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia13
Immunotherapy Use in Patients With Lung Cancer and Comorbidities13
Radiotherapy for Non-Hodgkin Lymphomas12
Tumor-Infiltrating Lymphocyctes in Triple-Negative Breast Cancer12
Central Nervous System Lymphoma11
Obesity and Energy Balance Considerations in Triple-Negative Breast Cancer11
Mechanistic Effects of Estrogens on Breast Cancer11
Development of Next-Generation Poly(ADP-Ribose) Polymerase 1–Selective Inhibitors10
Incorporating Value-Based Care Into Oncology9
Role of Microenvironment in Non-Hodgkin Lymphoma9
Interventional Pharmacoeconomics9
DNA Damage Repair Inhibitors—Combination Therapies8
Fecal Microbiota Transplantation as a Cancer Therapeutic8
Lessons for Oncology From the COVID-19 Pandemic8
c-Met Signaling as a Therapeutic Target in Head and Neck Cancer8
Neoantigen-Specific T Cells in Adoptive Cell Therapy8
Neurotoxicity Biology and Management7
DNA Damage Response in Glioblastoma7
PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations7
Monoclonal Antibodies in Acute Myeloid Leukemia—Are We There Yet?7
Marginal Zone Lymphomas7
Is There a Role for Cellular Therapy in Chronic Lymphocytic Leukemia?7
Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality-of-Life Outcomes in Previously Untreated Patients With Nonsquamous Non–Small Cell Lung Cancer7
Stereotactic Body Radiotherapy in Oligomestatic/Oligoprogressive Sarcoma7
Targeted Treatment of Triple-Negative Breast Cancer7
Mining the Microenvironment for Therapeutic Targets in Chronic Lymphocytic Leukemia6
Clinical Targeting of Altered Metabolism in High-Grade Glioma6
Targeting Metabolic Pathways in Kidney Cancer6
Measurable Residual Disease Assessment as a Surrogate Marker in New Drug Development in Acute Myeloid Leukemia6
The Critical Role of the Oncology Nurse as a Partner in the Management of Patients With Advanced Kidney Cancer6
COVID-19 and Chronic Lymphocytic Leukemia6
STING Agonists in Head and Neck Squamous Cell Carcinoma6
Overview of Lung Cancer Immunotherapy6
Surgical Considerations for Tumor Tissue Procurement to Obtain Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy6
Menopausal Hormone Therapy and Breast Cancer6
Antibody-Drug Conjugates in Breast Cancer: What Is Beyond HER2?6
Prognostic and Predictive Factors in Metastatic Renal Cell Carcinoma6
The Role of Radiolabeled Monoclonal Antibodies in Cancer Imaging and ADC Treatment6
Patterns of Enrollment in Cancer Treatment Trials During the COVID-19 Pandemic at National Cancer Institute–Designated Cancer Centers6
Moving Immunotherapy Into Early-Stage Lung Cancer6
Minimal Residual Disease in Multiple Myeloma6
What Are the Prospects for Treating TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia?5
Circulating Plasma Epstein-Barr Virus DNA Load During the Follow-up Periods Predicts Recurrence and Metastasis in Nasopharyngeal Carcinoma5
Advances in Treatment of Follicular Lymphoma5
Poly(ADP-Ribose) Polymerase Inhibitor Inhibition in Ovarian Cancer5
Autoimmune Cytopenia in CLL5
Toward the Next Generation of High-Grade Glioma Clinical Trials in the Era of Precision Medicine5
The Evolving Molecular Landscape of High-Grade Gliomas5
Therapeutic Targeting of FGFR Signaling in Head and Neck Cancer5
The von Hippel-Lindau Tumor Suppressor Gene5
The Menopause Management Vacuum5
Current State of Cell Therapies for Genitourinary Malignancies5
Current State of Cell Therapies for Breast Cancer5
Hormone Replacement Therapy After Breast Cancer5
0.052145957946777